Market Overview

UPDATE: Wedbush Raises PT to $20 on Celldex Therapeutics on Rindopepimut Outlook

Share:
Related CLDX
Celldex Offers Safety Profile, Immuno Response Data from Phase 1/2 Study of Varlilumab, Nivolumab at AACR Meeting
Benzinga's Top Downgrades

Wedbush maintained Celldex Therapeutics (NASDAQ: CLDX) with an Outperform rating and raised the price target from $8.00 to $20.00.

Wedbush analyst Gregory R. Wade noted, "We are increasing our price target to $20 from $8 based upon revised launch and peak penetration assumptions as emerging data to suggest a more targeted clinical path for both for rindopepimut and CDX-011. We have increased our peak penetration rate and duration of therapy in the front-line setting for rindopepimut from 45% and 9 cycles to, 65% and 18 cycles, respectively. We now see worldwide peak sales of rindopepimut north of $1 billion."

Celldex Therapeutics closed at $11.89 on Monday.

Latest Ratings for CLDX

DateFirmActionFromTo
Mar 2016JefferiesDowngradesBuyHold
Mar 2016Cowen & CompanyMaintainsOutperform
Mar 2016H.C. WainwrightMaintainsBuy

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

View Comments and Join the Discussion!